Institution: | 1. Department of Respiratory and Critical Care Medicine, The Fifth Affiliation Hospital of Zhengzhou University, No. 3 Kangfuqian Street, Zhengzhou, 450052 China
These authors contributed equally to this work.;2. School of Textiles, Zhongyuan University of Technology, No. 41 Zhongyuan Road (M), Zhengzhou, 450007 China
These authors contributed equally to this work.;3. Department of Respiratory and Critical Care Medicine, The Fifth Affiliation Hospital of Zhengzhou University, No. 3 Kangfuqian Street, Zhengzhou, 450052 China;4. School of Textiles, Zhongyuan University of Technology, No. 41 Zhongyuan Road (M), Zhengzhou, 450007 China;5. Intensive Care Unit, Zhengzhou Orthopedics Hospital, No. 56 Longhai Road, Zhengzhou, 450052 China;6. Henan Key Laboratory for Helicobacter pylori & Microbiota and GI Cancer, Marshall Medical Research Centre, The Fifth Affiliated Hospital of Zhengzhou University, No. 3 Kangfuqian Street, Zhengzhou, 450052 China |
Abstract: | Lung cancer is the leading cause of cancer deaths worldwide and most cancer patients receiving conventional chemotherapy suffer from severe side effects due to the non-selective effects of chemotherapeutic drugs on normal cells. Targeted nanomaterials can obtain excellent accumulation at the tumor site through their active or passive targeting mechanisms, thereby reducing the toxicity of the drugs in various ways. In this study, hyaluronic acid (HA) which could specifically bind to CD44 on the surface of tumor cells, was used to modify amine-caged platinum nanoclusters (Pt NCs-NH2) to obtain targeting HA-Pt NCs-NH2. Based on the differential expression of CD44 on the surface of three lung cells (non-small cell lung cancer cell H1299, small cell lung cancer cell H446, and embryonic lung fibroblast HFL1), HA-Pt NCs-NH2 can differentially enter the three cells and achieve their targeting of non-small cell lung cancer cell (NSCLC) cells. Pt NCs significantly inhibited the proliferation, migration and invasion of NSCLC cells and induced their apoptosis in comparison of classical cisplatin and carboplatin, showing a bright future in early diagnosis and treatment of NSCLC. |